Carcione Davide, Intra Jari, Andriani Lilia, Campanile Floriana, Gona Floriana, Carletti Silvia, Mancini Nicasio, Brigante Gioconda, Cattaneo Dario, Baldelli Sara, Chisari Mattia, Piccirilli Alessandra, Di Bella Stefano, Principe Luigi
Laboratory of Medicine and Microbiology, Busto Arsizio Hospital-ASST Valle Olona, 21052 Busto Arsizio, VA, Italy.
Clinical Chemistry Laboratory, Fondazione IRCCS San Gerardo Dei Tintori, 20900 Monza, MB, Italy.
Pharmaceuticals (Basel). 2023 Sep 15;16(9):1304. doi: 10.3390/ph16091304.
Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections. The objective of this review is to conduct an extensive examination of emerging treatments for Gram-positive infections including ceftobiprole, ceftaroline, dalbavancin, oritavancin, omadacycline, tedizolid, and delafloxacin. From a methodological standpoint, a comprehensive analysis on clinical trials, molecular structure, mechanism of action, microbiological targeting, clinical use, pharmacokinetic/pharmacodynamic features, and potential for therapeutic drug monitoring will be addressed. Each antibiotic paragraph is divided into specialized microbiological, clinical, and pharmacological sections, including detailed and appropriate tables. A better understanding of the latest promising advances in the field of therapeutic options could lead to the development of a better approach in managing antimicrobial therapy for multidrug-resistant Gram-positive pathogens, which increasingly needs to be better stratified and targeted.
抗生素耐药性是一个公共卫生问题，越来越多令人担忧的数据被报道。革兰氏阳性菌是严重医院感染和社区感染的主要致病菌之一。本综述的目的是对革兰氏阳性菌感染的新兴治疗方法进行广泛研究，包括头孢比罗、头孢洛林、达巴万星、奥利万星、奥玛环素、特地唑胺和德拉沙星。从方法学的角度来看，将对临床试验、分子结构、作用机制、微生物靶向性、临床应用、药代动力学/药效学特征以及治疗药物监测的潜力进行全面分析。每个抗生素段落都分为专门的微生物学、临床和药理学部分，包括详细且恰当的表格。更好地了解治疗选择领域的最新有前景进展，可能会为管理多重耐药革兰氏阳性病原体的抗菌治疗开发出更好的方法，而这日益需要更好地分层和靶向治疗。
